GL1X · GenesisL1 explorer

Research workbench

X-ray structural study of quinone reductase II inhibition by compounds with micromolar to nanomolar range IC50 values

Analyse X-ray structural study of quinone reductase II inhibition by compounds with… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
3OX1
Type
protein
Length
457 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Ribosyldihydronicotinamide dehydrogenase [quinone]
EC
1.10.99.2
UniProt
P16083
Ligands
FAD, 695, ZN
Pockets
2 · best druggability 0.78

Structure

x-ray diffraction · 2 distinct chains · 41% helix, 16% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ARibosyldihydronicotinamide dehydrogenase [quinone] (EC 1.10.99.2)protein22842% helix, 16% strandP16083
BRibosyldihydronicotinamide dehydrogenase [quinone] (EC 1.10.99.2)protein22940% helix, 16% strandP16083

Ligands and binding sites

  • FAD · Flavin-adenine dinucleotide · ligand · 2 copies · chains A, B
  • 695 · N-{2-[7-(methylsulfamoyl)naphthalen-1-yl]ethyl}acetamide · ligand · 2 copies · chains A, B
  • ZN · Zinc ion · metal · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
16030.780.8345FAD, 695
26220.760.8248FAD, 695

Interfaces

1 interface between chains.

  • A–B · 2012 Ų buried · 25 hydrogen bonds · protein-protein

Compared structures

  • 3OX1 · X-ray Structural study of qui reductase II inhibition by compounds with micromolar to… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.